| Literature DB >> 34868929 |
Luigi Carlo Turco1, Giuseppe Vizzielli1, Virginia Vargiu2, Salvatore Gueli Alletti1, Maria De Ninno3, Gabriella Ferrandina1,4, Luigi Pedone Anchora1, Giovanni Scambia1,4, Francesco Cosentino2,5.
Abstract
INTRODUCTION: A current challenge for endometriosis surgery is to correctly identify the localizations of disease, especially when small or hidden (occult endometriosis), and to exactly define their real extension. The use of near-infrared radiation imaging (NIR) after injection of indocyanine green (ICG) represents one of the most encouraging method. The aim of this study is to assess the diagnostic value of NIR-ICG imaging in the surgical treatment of endometriosis compared with the standard of treatment.Entities:
Keywords: deep infiltrating endometriosis; gynecological surgery; indocyanine green; near-infrared imaging; personalized medicine
Year: 2021 PMID: 34868929 PMCID: PMC8634028 DOI: 10.3389/fonc.2021.737938
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Surgical images using white light (WL) and near-infrared indocyanine green (NIR-ICG) mode. The first two pictures represent a rectosigmoid nodule using WL (A) and NIR-ICG mode (B). (C, D) Superficial peritoneal lesion in WL (D) and NIR-ICG (C). The last two pictures show retrocervical lesions with uterosacral ligament involvement using the two vision systems [WL in (E) and NIR-ICG in (F)].
Figure 2Study flow diagram.
Characteristics of the patients.
| Variables | Value | Percentage |
|---|---|---|
| All cases | 51 | 100% |
| Age, years (range) | 35 (26–47) | – |
| Body mass index (range) | 20.5 (14–33) | – |
| ASA class | ||
| 1 | 35 | 69% |
| 2 | 16 | 31% |
| 3 | 0 | – |
| Previous delivery | 18 | 35% |
| Prior surgery for endometriosis | 19 | 37% |
| Preoperative symptoms (VAS) | ||
| Dysmenorrhea | 9 (3–10) | 86% |
| Dyschezia | 7 (2–10) | 59% |
| Dysuria | 7 (4–10) | 18% |
| Dyspaurenia | 8 (1–10) | 67% |
| Chronic pelvic pain | 6 (2–10) | 69% |
| Stage | ||
| Stage I (minimal) | 0 | – |
| Stage II (mild) | 6 | 12% |
| Stage III (moderate) | 19 | 37% |
| Stage IV (severe) | 26 | 51% |
Data are shown as median/range for the referred positive VAS. Percentage refers to the number of patients according to symptoms.
Pain is valued with the visual analog scale (VAS) for symptomatic patients.
According to the rAFS classification.
Surgical procedures and perioperative data.
| Surgical procedure | Value | Percentage |
|---|---|---|
| Ovarian cyst removal | 26 | 51% |
| Peritoneal removal | 36 | 70% |
| Retrocervical nodule removal | 40 | 78% |
| Vaginal nodule removal | 14 | 27% |
| Uterosacral ligament nodule removal | 41 | 80% |
| Rectal nodule shaving | 12 | 23% |
| Segmental resection and anastomosis of sigma-rectum | 10 | 20% |
| Segmental resection and anastomosis of sigma-rectum plus ileostomy | 4 | 8% |
| Other procedures (appendectomy, salpingectomy, ureteral stent placement) | 14 | 27% |
| Operative time (min) | 142 (65–375) | – |
| Dose of ICG injected | 15 (10.25–24) | – |
| Intraoperative complications | 0 | – |
| Estimated blood loss (ml) | 100 (0–350) | – |
| Postoperative complications | ||
| Early | 9 | 17.6% |
| I | 2 | – |
| II | 5 | – |
| III | 2 | – |
| IV | 0 | – |
| Late | 0 | |
| Hospital stay (no. of days) | 2 (1–13) | – |
Data are shown as median/range.
According to Clavien–Dindo classification.
Intraoperative and pathologic data collection resulting from WL vision and the combination of the two techniques (WL plus NIR-ICG).
| Variables | WL visualization | Overall visualization (WL plus NIR-ICG) | Pathology for WL | Overall pathology (WL plus NIR-ICG) | True positive for WL | False positive for WL | True negative for WL | False negative for WL (s-OcL) | c-OcL |
|---|---|---|---|---|---|---|---|---|---|
| Peritoneal endometriosis | |||||||||
| White lesion | 21 | 24 | 17 | 20 | 17 | 4 | 21 | 3 | 3 |
| Black lesion | 16 | 16 | 15 | 15 | 15 | 1 | 16 | 0 | 0 |
| Deep infiltrating endometriosis | |||||||||
| Retrocervical nodule | 35 | 42 | 34 | 41 | 34 | 1 | 35 | 7 | 7 |
| USL nodule | 62 | 65 | 61 | 64 | 61 | 1 | 62 | 3 | 3 |
| Periureteral/ovarian fossa nodule | 20 | 31 | 20 | 31 | 20 | 0 | 20 | 11 | 11 |
| Vaginal nodule | 11 | 11 | 11 | 11 | 11 | 0 | 11 | 0 | 0 |
| Sigma-rectum nodule | 26 | 30 | 26 | 30 | 26 | 0 | 26 | 4 | 4 |
| Prevesical/vesical nodule | 16 | 21 | 16 | 21 | 16 | 0 | 16 | 5 | 5 |
| Overall endometriosis | |||||||||
| Total (PE and DIE) | 207 | 240 | 200 | 233 | 200 | 7 | 207 | 33 | 33 |
WL, white light visualization mode/expert surgeon eye; c-OcL, confirmed occult endometriosis lesion at WL (=FN); PE, superficial peritoneal endometriosis; DIE, deep infiltrating endometriosis.
True negative for WL = 51 control biopsies performed in WL.
Figure 3Graphical representation of the collection of intraoperative and pathological data derived from WL vision and the combination of the two techniques (WL plus NIR-ICG).
Intraoperative and pathologic data collection resulting from NIR-ICG.
| Variables | Overall NIR-ICG visualization | NIR-ICG visualization already seen in WL | Pathology for NIR-ICG | True positive for NIR-ICG | False positive for NIR-ICG | True negative for NIR-ICG | False negative for NIR-ICG | c-OcL |
|---|---|---|---|---|---|---|---|---|
| Peritoneal endometriosis | ||||||||
| White lesion | 14 | 11 | 13 | 13 | 1 | 14 | 7 | 7 |
| Black lesion | 9 | 9 | 9 | 9 | 0 | 9 | 6 | 6 |
| Deep infiltrating endometriosis | ||||||||
| Retrocervical nodule | 41 | 34 | 40 | 40 | 1 | 40 | 1 | 1 |
| USL nodule | 61 | 58 | 57 | 57 | 1 | 58 | 4 | 4 |
| Periureteral/ovarian fossa nodule | 29 | 18 | 29 | 29 | 0 | 29 | 2 | 2 |
| Vaginal nodule | 10 | 10 | 10 | 10 | 0 | 10 | 1 | 1 |
| Sigma-rectum nodule | 27 | 23 | 27 | 27 | 0 | 27 | 3 | 3 |
| Prevesical/vesical nodule | 15 | 10 | 15 | 15 | 0 | 15 | 6 | 6 |
| Overall endometriosis | ||||||||
| Total (PE and DIE) | 206 | 173 | 203 | 203 | 3 | 206 | 30 | 33 |
NIR-ICG, near-infrared visualization mode with indocyanine green; c-OcL, confirmed occult lesion at NIR-IGC (=FN at WL); PE, superficial peritoneal endometriosis; DIE, deep infiltrating endometriosis.
Number of control biopsies performed in NIR-ICG + TN of PE and DIE.
Comparison between the NIR-ICG and WL for each surgical site in the whole population.
| Variable | Vision | PPV (%) | NPV (%) | Sensitivity (%) | Specificity (%) | Accuracy (%) | McNemar’s test | Cohen’s kappa |
|---|---|---|---|---|---|---|---|---|
| Peritoneal endometriosis | ||||||||
| White lesion | WL | 81.0 | 87.5 | 85.0 | 84.0 | 46.7 | 0.301 | 0.667 |
| NIR-ICG | 92.9 | 66.7 | 65.0 | 93.3 | 40.0 | |||
| Black lesion | WL | 93.8 | 100 | 100 | 94.1 | 50.0 | 0.125 | 0.751 |
| NIR-ICG | 100 | 60.0 | 60.0 | 100 | 60.0 | |||
| Deep infiltrating endometriosis | ||||||||
| Retrocervical nodule | WL | 97.1 | 83.3 | 82.9 | 97.2 | 45.4 | 0.109 | 0.874 |
| NIR-ICG | 97.6 | 97.6 | 97.6 | 97.6 | 50.0 | |||
| USL nodule | WL | 98.4 | 95.4 | 95.3 | 98.4 | 48.8 | 0.179 | 0.927 |
| NIR-ICG | 98.3 | 93.5 | 93.4 | 98.3 | 48.3 | |||
| Periureteral/ovarian fossa nodule | WL | 100 | 64.5 | 64.5 | 100 | 39.2 |
| 0.768 |
| NIR-ICG | 100 | 93.5 | 93.5 | 100 | 48.3 | |||
| Vaginal nodule | WL | 100 | 100 | 100 | 100 | 50.0 | 1.0 | 0.960 |
| NIR-ICG | 100 | 90.9 | 90.9 | 100 | 47.6 | |||
| Sigma-rectum nodule | WL | 100 | 86.7 | 86.7 | 100 | 46.4 |
| 0.876 |
| NIR-ICG | 100 | 90.0 | 90.0 | 100 | 47.3 | |||
| Prevesical/vesical nodule | WL | 100 | 76.2 | 76.2 | 100 | 43.2 |
| 0.705 |
| NIR-ICG | 100 | 71.4 | 71.4 | 100 | 41.6 | |||
| Overall endometriosis | ||||||||
| Total (PE and DIE) | WL | 96.6 | 86.3 | 85.8 | 96.7 | 46.3 |
| 0.835 |
| NIR-ICG | 98.5 | 87.1 | 87.0 | 98.5 | 46.5 | |||
NIR-ICG, near-infrared visualization vision with indocyanine green; WL, white light vision; PPV, positive predictive value; NPV, negative predictive value; PE, superficial peritoneal endometriosis; DIE, deep infiltrating endometriosis.
The bold style means that the values reported are statistic significant.
Figure 4ROC curves of the two approaches (white light and near-infrared indocyanine green).